Time‐Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma
Open Access
- 13 April 2019
- journal article
- research article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 8 (6) , 415-427
Abstract
Avelumab, a human anti–programmed death ligand 1 immunoglobulin G1 antibody, has shown efficacy and manageable safety in multiple tumors. A two‐compartment population pharmacokinetic model for avelumab incorporating intrinsic and extrinsic covariates and time‐varying clearance (CL) was identified based on data from 1,827 patients across three clinical studies. Of 14 tumor types, a decrease in CL over time was more notable in metastatic Merkel cell carcinoma and squamous cell carcinoma of the head and neck, which had maximum decreases of 32.1% and 24.7%, respectively. The magnitude of reduction in CL was higher in responders than in nonresponders. Significant covariate effects of baseline weight, baseline albumin, and sex were identified on both CL and central distribution volume. Significant covariate effects of black/African American race, C‐reactive protein, and immunogenicity were found on CL. None of the covariate or time‐dependent effects were clinically important or warranted dose adjustment.Keywords
Funding Information
- Pfizer
This publication has 28 references indexed in Scilit:
- Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal AntibodiesClinical Pharmacokinetics, 2013
- Local Inflammation and Human Papillomavirus Status of Head and Neck CancersJAMA Otolaryngology–Head & Neck Surgery, 2012
- Physiochemical and Biochemical Factors Influencing the Pharmacokinetics of Antibody TherapeuticsThe AAPS Journal, 2012
- Fixed Dosing Versus Body Size—Based Dosing of Monoclonal Antibodies in Adult Clinical TrialsThe Journal of Clinical Pharmacology, 2009
- Kinetics of FcRn-mediated recycling of IgG and albumin in human: Pathophysiology and therapeutic implications using a simplified mechanism-based modelClinical Immunology, 2007
- PsN-Toolkit—A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEMComputer Methods and Programs in Biomedicine, 2005
- Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programmingComputer Methods and Programs in Biomedicine, 2004
- Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockadeProceedings of the National Academy of Sciences, 2002
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasionNature Medicine, 2002
- Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEMComputer Methods and Programs in Biomedicine, 1998